Nanobiotix S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Nanobiotix S.A. for the month of March 2026. The filing, dated March 25, 2026, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a financial statement.
Material Changes
The filing text does not provide data to compare against prior periods. No material financial changes are detailed within the provided text.
Guidance, Outlook, and Risks
The filing references a press release dated March 25, 2026, which is attached as Exhibit 99.1. The text of this filing does not contain the content of the press release, nor does it provide specific guidance, management commentary, risks, contingencies, or details on unusual items.
Investor Verification Checklist
- Review the full text of the press release attached as Exhibit 99.1 to understand the specific announcement made on March 25, 2026.
- Verify the impact of the announced event on the company's clinical pipeline or financial position, as this is not detailed in the Form 6-K cover page.
- Check subsequent filings for any updated financial guidance or risk disclosures related to the March 2026 announcement.